CorMedix Inc. (CRMD) stock forecast and price target
Price $4.66 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($4.66)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $0.43 | — | $335M |
| Next fiscal year ends December 31, 2027 | $-0.06 | — | $316M |
| Next quarter ends December 31, 2026 | $-0.16 | — | $52M |
| Quarter after ends March 31, 2027 | $-0.06 | — | $68M |
Consensus of the analysts covering CorMedix, updated daily. In the last 30 days 2 estimates were raised and 3 lowered.
Our model vs. Wall Street
Analysts see 196.1% upside over 12 months. Our discounted cash flow model with moderate assumptions puts CorMedix’s intrinsic value about 65% below today’s market value, and it scores 3.0 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the CorMedix stock price target?
The average 12-month target from 5 analysts is $13.80, 196.1% above the current price of $4.66 Targets range from $12.00 to $17.00.
Is CorMedix a buy according to analysts?
The consensus rating is “Buy” (3 strong buy, 2 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is CorMedix expected to earn?
Analysts expect EPS of $0.43 for the fiscal year ending December 31, 2026 and $-0.06 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.